-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari Therapeutics Collaborates With WuXi XDC Over Development Of Novel PH1 Payload

Benzinga·04/06/2026 12:46:20
Listen to the news

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari's novel PH1 payload.